The global dual GIP/ GLP-1 receptor agonists obesity drugs market size was valued at USD 4.75 billion in 2024 and is expected to reach USD 17.71 billion by 2032, at a CAGR of 17.85% during the forecast period
The market growth is largely fueled by the increasing prevalence of obesity and related metabolic disorders globally, coupled with the rising demand for more effective, long-acting pharmacological treatments. Dual GIP/GLP-1 receptor agonists are emerging as a promising class of drugs that offer superior weight reduction and glycemic control compared to earlier monotherapy options
Furthermore, growing investments in clinical research, favourable regulatory pathways, and strategic collaborations between pharmaceutical companies are accelerating the development and commercialization of Dual GIP/GLP-1 receptor agonist therapies. These converging factors are driving widespread adoption and significantly boosting the growth of the Dual GIP/ GLP-1 Receptor Agonists Obesity Drugs market
